Form 4: Immunocore R&D Head Sells Shares
Insider Transaction Report
Immunocore's Head of R&D, David M. Berman, exercised stock options and sold a total of 31,913 ordinary shares for approximately $1.28 million under a pre-arranged trading plan.
Summary
- David M. Berman, Head of R&D at Immunocore Holdings plc, engaged in stock option exercises and subsequent sales of ordinary shares.
- On December 4, 2025, Berman exercised options to acquire 31,341 ordinary shares at an exercise price of $17.46 per share.
- Immediately following, he sold these 31,341 shares at a weighted average price of $40.26 per share.
- On December 5, 2025, Berman exercised options for an additional 572 ordinary shares at $17.46 per share.
- These 572 shares were then sold at a weighted average price of $40.14 per share.
- All transactions were conducted under a Rule 10b5-1 trading plan established on May 9, 2025.
Sentiment
Score: 6
Explanation: The transactions represent a planned exercise of stock options and subsequent sale of shares by a key executive, indicating a realization of compensation rather than a reaction to new company-specific news. The pre-arranged nature mitigates negative interpretations of insider selling.
Positives
- The Reporting Person realized a substantial gain by exercising options at $17.46 and selling shares at weighted average prices of $40.26 and $40.14.
- The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating planned activity rather than an immediate reaction to new, undisclosed information.
Negatives
- The Head of R&D sold a significant number of shares, which could be interpreted as a reduction in direct equity exposure by a key executive.
Future Outlook
NA
Industry Context
NA
Related Party Transactions
- David M. Berman, Head of R&D, exercised employee stock options and subsequently sold the acquired ordinary shares.
Stakeholder Impact
- Shareholders may observe a reduction in direct equity holdings by a key executive, though the planned nature of the transactions under a Rule 10b5-1 plan lessens immediate concern.
- The transactions reflect a standard executive compensation mechanism (stock options) being exercised and monetized.
Key Dates
| Date | Description |
|---|---|
| 05/09/2025 | Rule 10b5-1 trading plan adopted by the Reporting Person. |
| 12/04/2025 | Exercise of 31,341 employee share options and subsequent sale of 31,341 ordinary shares. |
| 12/05/2025 | Exercise of 572 employee share options and subsequent sale of 572 ordinary shares. |
| 12/08/2025 | Date of filing of the Form 4. |
| 09/12/2028 | Expiration date of the exercised employee share options. |
Recommendation
holdThe filing details a routine, pre-planned exercise of stock options and subsequent sale of shares by a key executive. While it represents insider selling, the execution under a Rule 10b5-1 plan suggests it is part of a long-term compensation strategy rather than a reaction to new, undisclosed negative information. Therefore, it does not provide a basis for a change in investment recommendation.
Keywords
Immunocore, IMCR, Form 4, insider trading, stock options, share sale, executive compensation, David M. Berman, R&D
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.